| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 0.56 [0.31, 1.00] | | < 1 | | 0% | 6 studies (6/-) | 97.4 % | some concern | not evaluable | moderate | crucial | - |
| deaths | 0.84 [0.64, 1.10] | | < 1 | | 0% | 26 studies (26/-) | 90.1 % | some concern | critical | moderate | crucial | - |
| deaths (time to event analysis only) | 0.64 [0.28, 1.48] | | < 1 | | 0% | 3 studies (3/-) | 85.1 % | some concern | not evaluable | moderate | crucial | - |
| clinical deterioration | 0.94 [0.70, 1.26] | | < 1 | | 20% | 11 studies (11/-) | 66.3 % | some concern | low | moderate | important | - |
| clinical improvement | 1.24 [0.98, 1.57] | | > 1 | | 67% | 14 studies (14/-) | 96.4 % | some concern | low | moderate | important | - |
| clinical improvement (14-day) | 1.24 [1.03, 1.48] | | > 1 | | 25% | 8 studies (8/-) | 98.9 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
| clinical improvement (28-day) | 1.47 [1.06, 2.04] | | > 1 | | 59% | 4 studies (4/-) | 99.0 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (7-day) | 1.21 [0.98, 1.50] | | > 1 | | 63% | 10 studies (10/-) | 96.3 % | some concern | critical | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.17 [0.99, 1.39] | | > 1 | | 67% | 12 studies (12/-) | 97.1 % | some concern | critical | moderate | important | - |
| hospital discharge | 1.16 [0.91, 1.48] | | > 1 | | 43% | 6 studies (6/-) | 87.7 % | some concern | serious | moderate | important | - |
| hospitalization | 0.12 [0.01, 2.26] | | < 1 | | 0% | 1 study (1/-) | 92.0 % | NA | not evaluable | | important | - |
| mechanical ventilation | 0.84 [0.48, 1.47] | | < 1 | | 39% | 11 studies (11/-) | 72.6 % | some concern | critical | moderate | important | - |
| mechanical ventilation (time to event analysis only) | 0.06 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | important | - |
| radiologic improvement (14-day) | 1.17 [0.42, 3.26] | | > 1 | | 16% | 3 studies (3/-) | 62.1 % | some concern | not evaluable | moderate | important | - |
| radiologic improvement (7-day) | 0.25 [0.02, 3.21] | | > 1 | | 76% | 4 studies (4/-) | 14.7 % | some concern | not evaluable | moderate | important | - |
| viral clearance | 1.31 [0.97, 1.77] | | > 1 | | 69% | 14 studies (14/-) | 95.9 % | some concern | low | moderate | important | - |
| viral clearance (time to event analysis only) | 1.35 [0.91, 2.02] | | > 1 | | 75% | 6 studies (6/-) | 93.0 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 14 | 1.32 [0.87, 2.01] | | > 1 | | 13% | 8 studies (8/-) | 90.3 % | some concern | serious | moderate | important | - |
| viral clearance by day 7 | 1.15 [0.85, 1.55] | | > 1 | | 67% | 11 studies (11/-) | 81.2 % | some concern | low | moderate | important | - |
| ICU admission | 1.19 [0.85, 1.67] | | < 1 | | 0% | 6 studies (6/-) | 15.6 % | some concern | not evaluable | moderate | non important | - |
| recovery | 1.03 [0.83, 1.28] | | > 1 | | 66% | 3 studies (3/-) | 60.0 % | some concern | not evaluable | moderate | non important | - |
| severe COVID-19 occurrence | 0.30 [0.07, 1.27] | | < 1 | | 0% | 1 study (1/-) | 94.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| serious adverse events | 0.75 [0.47, 1.19] | | < 1 | | 0% | 13 studies (13/-) | 89.0 % | some concern | critical | moderate | important | - |
| acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
| adverse events | 2.01 [1.41, 2.85] | | < 1 | | 69% | 17 studies (17/-) | 0.0 % | some concern | low | moderate | non important | - |
| arrhythmia | 2.24 [0.23, 21.69] | | < 1 | | 0% | 1 study (1/-) | 24.5 % | NA | not evaluable | | non important | - |
| elevated liver enzymes | 3.48 [1.40, 8.64] | | < 1 | | 0% | 1 study (1/-) | 0.4 % | NA | not evaluable | | non important | - |
| long QT | 9.79 [1.27, 75.50] | | < 1 | | 0% | 1 study (1/-) | 1.5 % | NA | not evaluable | | non important | - |
| renal impairment | 1.35 [0.47, 3.86] | | < 1 | | 0% | 1 study (1/-) | 28.8 % | NA | not evaluable | | non important | - |
| serious adverse events (SAE), any | 0.50 [0.32, 0.79] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
AE of interest endpoints 00 |
| Thromboembolic events | 0.89 [0.31, 2.55] | | < 1 | | 0% | 1 study (1/-) | 58.6 % | NA | not evaluable | | non important | - |
